Nathifa A. Moyo

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Conserved allomorphs of MR1 drive the specificity of MR1-restricted TCRs.

Conserved allomorphs of MR1 drive the specificity of MR1-restricted TCRs.

Journal: Frontiers in oncology
Published: April 18, 2024

Equine Arteritis Virus in Monocytic Cells Suppresses Differentiation and Function of Dendritic Cells.

Equine Arteritis Virus in Monocytic Cells Suppresses Differentiation and Function of Dendritic Cells.

Journal: Viruses
Published: December 11, 2022

Erratum: Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Erratum: Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Journal: Molecular therapy. Methods & clinical development
Published: May 26, 2022

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines.

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines.

Journal: Molecular therapy. Methods & clinical development
Published: January 18, 2021

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth.

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth.

Journal: Vaccines
Published: June 05, 2020

Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya.

Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya.

Journal: Vaccines
Published: May 04, 2020

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Journal: Molecular therapy. Methods & clinical development
Published: March 25, 2019

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Journal: Frontiers in immunology
Published: January 24, 2019

Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.

Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.

Journal: PLoS pathogens
Published: October 18, 2018

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA.

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA.

Journal: Molecular therapy. Methods & clinical development
Published: August 24, 2018

An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection.

An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection.

Journal: Mucosal immunology
Published: May 31, 2018

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Journal: PloS one
Published: January 08, 2018
Showing 1-12 of 17

Last Updated: 09/26/2026